VIP (Vasoactive Intestinal Peptide) vs PACAP

VIP and PACAP are structurally related neuropeptides that activate overlapping but distinct receptor systems. VIP is a 28-amino-acid peptide with established roles in vasodilation, bronchodilation, and immune regulation, and has been investigated in clinical contexts such as ARDS and pulmonary hypertension. PACAP exists primarily as PACAP-38, a 38-amino-acid peptide that is the predominant form in the central nervous system and shares 68% sequence identity with VIP. Despite this homology, PACAP exhibits unique signaling through the PAC1 receptor, which is linked to migraine pathophysiology and stress-related disorders. Researchers should note that while both peptides are studied for neuroscience applications, their evidence bases differ: VIP has a longer history in clinical and preclinical models, whereas PACAP research is more focused on mechanistic and translational studies in headache and psychiatric conditions.

VIP exerts its effects primarily through VPAC1 and VPAC2 receptors, which are G-protein-coupled receptors that activate adenylate cyclase and increase intracellular cAMP. Its 28-amino-acid sequence (MW ~3326.8 g/mol) is widely distributed in central and peripheral neurons, as well as in the lungs and gastrointestinal tract. Preclinical studies indicate that VIP reduces pro-inflammatory cytokine release and promotes regulatory T-cell activity, underpinning its immunomodulatory profile. The synthetic form aviptadil (RLF-100) was investigated in COVID-19-associated ARDS, where it showed potential for reducing lung injury and improving oxygenation. Additionally, VIP has been studied in pulmonary arterial hypertension models for its vasodilatory effects. Evidence for neuroprotection comes from in vitro and animal models, where VIP attenuates excitotoxicity and oxidative stress. However, its very short plasma half-life (~1–2 minutes) poses a significant limitation for in vivo research, often requiring continuous infusion or stable analogs.

PACAP acts through three receptors: PAC1, VPAC1, and VPAC2, with PAC1 being the primary mediator of its unique effects. The predominant form, PACAP-38 (MW ~4534.3 g/mol), is highly expressed in the brain, particularly in the hypothalamus, brainstem, and trigeminal ganglion. Research has established PACAP as a potent inducer of migraine-like attacks in human studies; intravenous infusion of PACAP-38 triggers delayed headache and photophobia in migraineurs, implicating PAC1 receptor activation and mast cell degranulation. Preclinical models also suggest a role in PTSD pathophysiology, where PACAP levels are elevated and correlate with symptom severity. Neuroprotective effects have been demonstrated in models of stroke, traumatic brain injury, and neurodegenerative diseases, likely through cAMP/PKA and MAPK pathways. Unlike VIP, PACAP-38 has a longer half-life (~5–10 minutes) but still requires careful dosing in experimental settings. The evidence base is robust for migraine and stress biology, while neuroprotection remains an active area of investigation.

Both VIP and PACAP are investigated in neuroscience research, particularly for neuroprotection and modulation of neuroinflammation. VIP is also widely studied in pulmonary research, including models of acute lung injury, asthma, and pulmonary hypertension, where its bronchodilatory and anti-inflammatory effects are leveraged. In immunomodulation research, VIP is used to explore regulatory T-cell induction and cytokine balance in autoimmune and inflammatory conditions. PACAP, by contrast, is predominantly studied in migraine research, where it serves as a reliable trigger for experimental headache models and a tool to probe PAC1 receptor mechanisms. Additionally, PACAP is investigated in PTSD research, given its role in stress circuitry and HPA axis regulation. Researchers should consider these distinct application domains when selecting a peptide, as VIP is more appropriate for pulmonary and broad immunomodulatory studies, while PACAP is better suited for headache and stress-related paradigms.

VIP has a very short plasma half-life (~1–2 minutes), which limits systemic exposure but necessitates continuous infusion for sustained effects. The primary dose-limiting adverse effect in clinical studies is hypotension due to potent vasodilation; flushing and diarrhea have also been reported at higher doses, consistent with its physiological role in gastrointestinal secretion. In research settings, careful dose titration and monitoring of blood pressure are recommended. PACAP, as an endogenous neuropeptide, is not typically administered therapeutically, but intravenous infusion in human studies has been associated with headache, flushing, and palpitations in both healthy volunteers and migraine patients. These effects are attributed to potent vasodilation and mast cell activation, which may also cause hypotension and allergic-type reactions. Researchers using PACAP should be aware of its potential to provoke migraine-like symptoms and should consider excluding individuals with a history of headache disorders from experimental protocols. Both peptides require appropriate handling and ethical oversight in human studies.